{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-134558","form_type":"8-K","ticker":"ACHV","cik":"0000949858","company_name":"ACHIEVE LIFE SCIENCES, INC.","filed_at":"2024-12-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:11.467823+00:00","generated_at":"2026-05-29T06:03:26.551339+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Achieve Life Sciences appoints Mark K. Oki as CFO effective December 5, 2024","bullets":["Mark Oki previously CFO of Aytu Biopharma, Vivus LLC, Alexza Pharmaceuticals.","Base salary $450,000/year; annual discretionary bonus up to 40% of base.","Awarded option for 72,000 shares (1/3 vest year 1, then monthly) and 168,000 performance-based RSUs.","Severance: 12 months salary (24 months on change in control) plus healthcare and accelerated equity vesting."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-134558","json":"https://secwatch.observer/filing/0000950170-24-134558.json","markdown":"https://secwatch.observer/filing/0000950170-24-134558.md","text":"https://secwatch.observer/filing/0000950170-24-134558.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/949858/000095017024134558/0000950170-24-134558-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/949858/000095017024134558/achv-20241205.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T06:03:26.551339+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}